Evidence map›Paper›PMID 32170410›Full record

ArticleArchives of gynecology and obstetrics2020

Factors influencing the time to surgery after neoadjuvant chemotherapy in breast cancer patients.

Carolin Müller, Ingolf Juhasz-Böss, Gilda Schmidt, Peter Jungmann, Erich-Franz Solomayer, Georg-Peter Breitbach, Stephanie Juhasz-Böss

Abstract read
In one paragraph

Article in Archives of gynecology and obstetrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carolin MüllerDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center, Kirrbergerstraße 100, 66424, Homburg/Saar, Germany. carolin.mueller@uks.eu.ORCID http://orcid.org/0000-0003-3488-5073
Ingolf Juhasz-BössDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center, Kirrbergerstraße 100, 66424, Homburg/Saar, Germany.
Gilda SchmidtDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center, Kirrbergerstraße 100, 66424, Homburg/Saar, Germany.
Peter JungmannDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center, Kirrbergerstraße 100, 66424, Homburg/Saar, Germany.
Erich-Franz SolomayerDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center, Kirrbergerstraße 100, 66424, Homburg/Saar, Germany.
Georg-Peter BreitbachDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center, Kirrbergerstraße 100, 66424, Homburg/Saar, Germany.
Stephanie Juhasz-BössDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center, Kirrbergerstraße 100, 66424, Homburg/Saar, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIt is suspected that delayed surgery after neoadjuvant chemotherapy (NACT) leads to a worse outcome in breast cancer patients. We therefore evaluated possible influencing factors of the time interval between the end of NACT and surgery.

methodsAll patients receiving NACT due to newly diagnosed breast cancer from 2015 to 2017 at the Department of Gynecology, Saarland University Medical Center, were included. The time interval between end of NACT and surgery was defined as primary endpoint. Possible delaying factors were investigated: age, study participation, outpatient and inpatient presentations, implants/expander, MRI preoperatively, discontinuation of chemotherapy, and genetic mutations.

resultsData of 139 patients was analyzed. Median age was 53 years (22-78). The time interval between end of NACT and surgery was 28 days (9-57). Additional clinical presentations on outpatient basis added 2 days (p = 0.002) and on inpatient basis added 7 days to time to surgery (p < 0.001). Discontinuation of NACT due to chemotherapy side effects prolonged time to surgery by 8 days (p < 0.001), whereas discontinuation due to disease progress did not delay surgery (p = 0.6). In contrast, a proven genetic mutation shortened time to surgery by 7 days (p < 0.001). Patient's age, participation in clinical studies, oncoplastic surgery, and preoperative MRI scans did not delay surgery.

conclusionBreast care centers should emphasize a reduction of clinical presentations and a good control of chemotherapy side effects for breast cancer patients to avoid delays of surgery after NACT.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantFemaleHumansMiddle AgedTime FactorsTreatment OutcomeYoung AdultBreast cancerDelaying factorsNeoadjuvant therapyTime to surgery

Identifiers

PMID32170410
PMCPMC7103004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.